DOTA-?NHS-?ester

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

DOTA-NHS-ester 是 Affibody 分子的连接体，应用于小动物 PET、SPECT 和 CT。 DOTA-NHS-酯可用于标记放射治疗剂或用于肿瘤检测的成像探针。

DOTA-NHS-ester is a linker for affibody molecules and is applied in small animals PET, SPECT, and CT. DOTA-NHS-ester can be used to label radiotherapeutic agents or imaging probes for the detection of tumors.(In Vitro):DOTA-NHS-ester can be used to modify human serum albumin (HSA) to produce DOTA-HSA. And DOTA-HSA is furtherly modified by Sulfo-SMCC to obtain DOTA-HSA-SMCC. DOTA-HSA-SMCC is conjugated to ZHER2:342 and the final product is DOTA-HSA-ZHER2:342. In a cell uptake assay, DOTA-HSA-ZHER2:342 is labeled by 64Cu, 64Cu-DOTA-HSA-ZHER2:342 (0.5-2 hours) slowly accumulates in the SKOV3 cells and reaches 0.71% of the applied activity at 0.5 h and the uptake increased to 1.58% at 2 h.(In Vivo):In a microPET images of a mouse bearing SKOV3 tumor, 64Cu-DOTA-HSA-ZHER2:342 is injected to the mouse tail. microPET images of a mouse bearing SKOV3 tumor at 1, 4, 24 and 48 h after tail vein injection.The SKOV3 tumor is visible with a low tumor-to-background contrast at 1 h post-injection (p.i.), but with a very good tumor-to-background contrast at 4 and 24 h p.i.Quantification analysis reveals that the SKOV3 tumor uptake values increases with time and are found to be 5.63%, 9.98%, 14.34% and 14.12% ID/g at 1, 4, 24, and 48 h, respectively.

DOTA-NHS-ester can be used to modify human serum albumin (HSA) to produce DOTA-HSA. And DOTA-HSA is furtherly modified by Sulfo-SMCC (HY-D0975) to obtain DOTA-HSA-SMCC. DOTA-HSA-SMCC is conjugated to ZHER2:342 and the final product is DOTA-HSA-ZHER2:342. In a cell uptake assay, DOTA-HSA-ZHER2:342 is labeled by 64Cu, 64Cu-DOTA-HSA-ZHER2:342 (0.5-2 hours) slowly accumulates in the SKOV3 cells and reaches 0.71% of the applied activity at 0.5 h and the uptake increased to 1.58% at 2 h.

In a microPET images of a mouse bearing SKOV3 tumor, 64Cu-DOTA-HSA-ZHER2:342 is injected to the mouse tail. microPET images of a mouse bearing SKOV3 tumor at 1, 4, 24 and 48 h after tail vein injection.The SKOV3 tumor is visible with a low tumor-to-background contrast at 1 h post-injection (p.i.), but with a very good tumor-to-background contrast at 4 and 24 h p.i.Quantification analysis reveals that the SKOV3 tumor uptake values increases with time and are found to be 5.63%, 9.98%, 14.34% and 14.12% ID/g at 1, 4, 24, and 48 h, respectively.

——

Others

Other Targets

CB1| Human Endogenous Metabolite

——

——

170908-81-3

501.49

C20H31N5O10

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (99.70 mM)

O=C(ON1C(CCC1=O)=O)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2

——

(-20℃)

With Ice Pack

≥ 2 years